Short answer
Incyte (INCY) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results covered quarter ended June 30, 2026.
Incyte 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results covered quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1.67B, up 38%, with GAAP net income $586M and diluted EPS $2.81
- Opzelura sales $450M, up 173%, including a $246M one-time CMS-related non-cash benefit
- Underlying Opzelura sales $204M, up 24%, signaling commercial growth beyond the accounting benefit
- 2026 sales guidance raised to $5.13B-$5.26B, while expense guidance rises for Vega acquisition costs
- Vega acquired for $1.25B, adding Phase 3 latarcibart and potential milestone payments up to $750M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Incyte 8-K filings
Get the next INCY 8-K as it lands
Follow INCY for push alerts, or ask the research agent what this filing means.